Subsequently, Ernst et al reported successful treatment with a combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in a patient with BRAF V600E‐mutated refractory myeloma.37 This evidence concerns the gene MAP2K7 and plasma cell myeloma.